WHO Pharmaceuticals Newsletter 1999, No. 07&08
(1999; 18 pages)
Table of Contents
Close this folderRegulatory actions
View the documentAlbumin (human): review of safety: conclusions: UK
View the documentAstemizole: voluntary withdrawal: Janssen, USA
View the documentCisapride: revised labelling: QT syndrome and drug interactions: USA
View the documentFollitropin alfa: batch withdrawn: stability problems: EU
View the documentHetastarch (hydroxyethylstarch): fatal haemorrhages: France
View the documentMinocycline: immunoallergic and liver damage with long-term therapy: Germany
View the documentOral contraceptives containing gestodene or desogestrel: update: revised product information: UK
View the documentPemoline: revised labelling: liver function monitoring: Abbott, USA
View the documentPhenol: warning concerning topical solutions: New Zealand
View the documentProgestational drug products: requirements for patient labelling: proposed rule: USA
View the documentSubstandard medicines: distribution and prescription prohibited: Venezuela
View the documentSunscreen products: requirements: final rule: USA
View the documentTranylcypromine/trifluoperazine: licence not renewed: UK
View the documentTroglitazone: restricted indications: USA
View the documentTrovafloxacin and alatrofloxacin: suspended: Spain
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
Open this folder and view contentsMedical devices
Open this folder and view contentsMedication errors
Open this folder and view contentsGeneral information
 

Trovafloxacin and alatrofloxacin: suspended: Spain

Spain. Further to the action taken by the European Agency for the Evaluation of Medicinal Products (EMEA), the Spanish Medicines Agency has suspended the use of medicinal products contain the fluoroquinolone antibiotic, trovafloxacin (Trovan, Turvel: Pfizer, Roerig) and the intravenous formulation of the drug, alatrofloxacin (Trovan IV, Turvel IV: Pfizer, Roerig), with effect from 15 June 1999.

[See also Alert No. 85: Trovafloxacin and alatrofloxacin: serious severe and unpredictable liver injuries dated 27 May 1999 and Alert No. 86: Trovafloxacin and alatrofloxacin: suspension & warnings: hepatotoxicity dated 22 June 1999]

Reference: Communication from the Agencia Española de Medicamento, Ministerio de Sanidad y Consumo, Madrid, 15 June 1999.

 

to previous section to next section
 

Last updated: May 3, 2013